Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention

Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention

Epidermal growth factor receptor (EGFR) mutations occur in about 50% of lung adenocarcinomas in Asia and about 15% in the US. EGFR mutation-specific inhibitors have been developed and made significant contributions to controlling EGFR mutated non-small cell lung cancer. However, resistance frequentl...

Full description

Bibliographic Details
Main Authors: Jing Pan, Donghai Xiong, Qi Zhang, Katie Palen, Robert H. Shoemaker, Bryon Johnson, Shizuko Sei, Yian Wang, Ming You
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Immunology
Subjects:
precision immunoprevention
immunointerception
EGFR mutation
peptide vaccine
MHC class II
T cell
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1036563/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1036563/full

Similar Items